Investments
65Portfolio Exits
12Funds
2About NGN Capital
NGN BioMed I, L.P. is a Venture Capital fund dedicated to Healthcare investing, focusing on ventures with the potential to achieve above average private equity returns with an emphasis on later stage investments. The Fund has flexibility to invest in a broad cross section of Healthcare and Biotechnology segments including drug products, medical devices and other healthcare segments like services. The fund is diversified by stage, from later stage to selected early stage opportunities, as well as by geography by investing predominantly in the US and in Europe.

Want to inform investors similar to NGN Capital about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Latest NGN Capital News
Jan 17, 2017
News January 17, 2017 —by LeapRate Staff 0 Pinterest The U.S. Securities and Exchange Commission has announced that 10 investment advisory firms have agreed to pay penalties ranging from $35,000 to $100,000 to settle charges that they violated the SEC’s investment adviser pay-to-play rule by receiving compensation from public pension funds within two years after campaign contributions made by the firms’ associates. According to the SEC’s orders, investment advisers are subject to a two-year timeout from providing compensatory advisory services either directly to a government client or through a pooled investment vehicle after political contributions were made to a candidate who could influence the investment adviser selection process for a public pension fund or appoint someone with such influence. The SEC’s orders find that these 10 firms violated the two-year timeout by accepting fees from city or state pension funds after their associates made campaign contributions to elected officials or political candidates with the potential to wield influence over those pension funds. “The two-year timeout is intended to discourage pay-to-play practices in the investment of public money, including public pension funds,” said LeeAnn Ghazil Gaunt, Chief of the SEC Enforcement Division’s Public Finance Abuse Unit. “Advisory firms must be mindful of the restrictions that can arise from campaign contributions made by their associates.” Without admitting or denying the findings, the 10 firms consented to the SEC’s orders finding they violated Section 206(4) of the Investment Advisers Act of 1940 and Rule 206(4)-5. The firms are censured and must pay the following monetary penalties: Adams Capital Management – $45,000
NGN Capital Investments
65 Investments
NGN Capital has made 65 investments. Their latest investment was in Visum Pharma as part of their Unattributed VC on September 9, 2023.

NGN Capital Investments Activity

Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
9/13/2023 | Unattributed VC | Visum Pharma | $0.05M | Yes | 1 | |
4/6/2022 | Series A | AcuamarkDx | $11.3M | No | 2 | |
3/7/2022 | Series F | Cerapedics | $25M | No | 2 | |
1/14/2021 | Seed VC - II | |||||
9/25/2019 | Seed VC - II |
Date | 9/13/2023 | 4/6/2022 | 3/7/2022 | 1/14/2021 | 9/25/2019 |
---|---|---|---|---|---|
Round | Unattributed VC | Series A | Series F | Seed VC - II | Seed VC - II |
Company | Visum Pharma | AcuamarkDx | Cerapedics | ||
Amount | $0.05M | $11.3M | $25M | ||
New? | Yes | No | No | ||
Co-Investors | |||||
Sources | 1 | 2 | 2 |
NGN Capital Portfolio Exits
12 Portfolio Exits
NGN Capital has 12 portfolio exits. Their latest portfolio exit was Exosome Diagnostics on June 25, 2018.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
6/25/2018 | Acquired | 2 | |||
11/28/2016 | Acquired | 7 | |||
9/30/2016 | IPO | Public | 1 | ||
Date | 6/25/2018 | 11/28/2016 | 9/30/2016 | ||
---|---|---|---|---|---|
Exit | Acquired | Acquired | IPO | ||
Companies | |||||
Valuation | |||||
Acquirer | Public | ||||
Sources | 2 | 7 | 1 |
NGN Capital Fund History
2 Fund Histories
NGN Capital has 2 funds, including NGN BioMed Opportunity I.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
---|---|---|---|---|---|
9/30/2005 | NGN BioMed Opportunity I | Late-Stage Venture Capital | Closed | $250M | 1 |
NGN BioMed Opportunity II |
Closing Date | 9/30/2005 | |
---|---|---|
Fund | NGN BioMed Opportunity I | NGN BioMed Opportunity II |
Fund Type | Late-Stage Venture Capital | |
Status | Closed | |
Amount | $250M | |
Sources | 1 |
NGN Capital Team
9 Team Members
NGN Capital has 9 team members, including , .
Name | Work History | Title | Status |
---|---|---|---|
Georg Nebgen | MPM Capital, Merck & Co., and Roche | Founder | Current |
Name | Georg Nebgen | ||||
---|---|---|---|---|---|
Work History | MPM Capital, Merck & Co., and Roche | ||||
Title | Founder | ||||
Status | Current |